The CMA Phase 1 decision is a procedural step; the remedy package mirrors the EC's already-agreed divestiture. Watch for the CMA's Phase 2 decision and any conditions beyond the proposed remedy. The early 2027 closing timeline remains intact.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $37.07entry
- T+1 · 5d ago −1.78%α −1.43% · $36.41
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
AkzoNobel and Axalta issued a joint press release acknowledging the UK CMA's Phase 1 decision identifying competition concerns in the UK vehicle refinish coatings market. The companies plan to address this with the same remedy package already agreed with the European Commission, involving the divestment of AkzoNobel's European VR coatings business. They remain confident the merger will close by early 2027.
Key Facts
- CMA Phase 1 decision identifies competition concerns solely in UK vehicle refinish coatings supply
- AkzoNobel and Axalta propose same remedy as agreed with European Commission: divestment of AkzoNobel's European VR coatings business including UK
- Companies remain confident merger will complete by early 2027
- Combined entity would have approximately $17 billion in revenue
- Shareholders of both companies already voted in favor on August 5, 2026
Financial Impact
Merger valued at approximately $17B combined revenue; no deal value stated in this release
Risk Factors
- CMA may require additional remedies beyond the proposed divestiture, potentially delaying or altering the merger
- Regulatory approvals in other jurisdictions could still impose conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3400482 |
Track record
44 reports on AXTA
5 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +16.39% at T+60 after the Jun 3, 2026 report. 6 of 10 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry price pending
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $36.41 to $36.56 Now $36.10 −0.85% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.10 −0.85% ▲ +0.41% +0.78% vs SPY
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $36.41 to $36.56 Now $36.10 −0.85% ▲ +0.41% +0.78% vs SPY
- Nov 11, 20265d ago Press Release Neutral 4/10 Viewing Entry $37.07 to $36.41 Now $36.10 −2.62% ▼ −1.78% −1.43% vs SPY
- Nov 6, 202610d ago 425 Neutral 5/10 Entry $37.53 to $37.38 Now $36.10 −3.81% ▼ −0.40% −0.03% vs SPY
- Nov 6, 202610d ago 425 Bullish 6/10 Entry $36.45 to $37.53 Now $36.10 −0.96% ▲ +2.96% +0.60% vs SPY
- Nov 6, 202610d ago Press Release Bullish 5/10 Entry $36.45 to $37.53 Now $36.10 −0.96% ▲ +2.96% +0.60% vs SPY
- Oct 29, 202618d ago 425 Bearish 4/10 Entry $34.07 to $35.84 Now $36.10 −5.96% ▼ −5.20% −5.67% vs SPY
- Oct 29, 202618d ago 425 Neutral 4/10 Entry $34.07 to $35.84 Now $36.10 +5.96% ▲ +5.20% +5.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers